Clinical Research Directory
Browse clinical research sites, groups, and studies.
RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection
Sponsor: West China Hospital
Summary
In Asia, hepatocellular carcinoma (HCC) commonly occurred in the underlying hepatitis B virus (HBV)-related liver disease.Curative therapies could improve the prognosis of HCC patients. However, tumor recurrence after curative therapy remains high with a 5-year recurrence rate \>70%.The risk for HCC development is increased for patient with HBV infection,but there was no consensus about which kind of oral antiviral treatment was the best option in the prevention of HBV related HCC recurrence after curative treatment.Therefore, we conducted this study to investigate the different effects of nucleotides(TDF) and nucleosides(ETV) on the prognosis of HBV-related HCC after curative resection.
Official title: The Different Effects of Nucleotide and Nucleoside Analogues on the Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients After Curative Resection:a Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 69 Years
Study Type
INTERVENTIONAL
Enrollment
104
Start Date
2017-07-01
Completion Date
2026-07-01
Last Updated
2022-05-25
Healthy Volunteers
No
Conditions
Interventions
Tenofovir Disoproxil
patients with HBV-HCC would take TDF as antiviral therapy before curative treatment to see the prognosis after surgery
Entecavir
patients with HBV-HCC would take ETV as antiviral therapy before curative treatment to see the prognosis after surgery
Locations (1)
West China Hospital, Sichuan University
Chengdu, Sichuan, China